Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers
| Status: | Recruiting |
|---|---|
| Conditions: | Lung Cancer, Skin Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/10/2019 |
| Start Date: | September 1998 |
| End Date: | April 2022 |
The purpose of this study is to identify and confirm new blood and tissue markers for
prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has
been shown to increase the risk of tumor spread and enhance tumor resistance to the standard
treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently
identified several proteins or markers in the blood and in tumors (including osteopontin,
lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that
may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.
prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has
been shown to increase the risk of tumor spread and enhance tumor resistance to the standard
treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently
identified several proteins or markers in the blood and in tumors (including osteopontin,
lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that
may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.
The endpoints of the study are
1. To validate the prognostic significance of OPN in H&N and lung cancer patients and to
monitor its level during active therapy and follow up for cancer surveillance.
2. To identify a gene and protein signature for hypoxia in H&N and lung cancer patients.
1. To validate the prognostic significance of OPN in H&N and lung cancer patients and to
monitor its level during active therapy and follow up for cancer surveillance.
2. To identify a gene and protein signature for hypoxia in H&N and lung cancer patients.
Inclusion Criteria:Newly diagnosed patients with head and neck cancer who has tumor
accessible to tumor oxygenation measurement with a microelectrode.
We found this trial at
1
site
291 Campus Dr
Stanford, California 94305
Stanford, California 94305
(650) 725-3900
Principal Investigator: Quynh-Thu Le
Phone: 650-724-4606
Stanford University School of Medicine Vast in both its physical scale and its impact on...
Click here to add this to my saved trials
